Coronary microvascular dysfunction in women with nonobstructive ischemic heart disease as assessed by positron emission tomography

Roxana Campisi¹², Fernando D. Marengo³

¹Department of Nuclear Medicine and Cardiovascular Imaging, Diagnóstico Maipú, Buenos Aires, Argentina; ²Department of Nuclear Medicine, Instituto Argentino de Diagnóstico y Tratamiento S.A., Buenos Aires, Argentina; ³Laboratorio de Fisiología y Biología Molecular, Instituto de Fisiología, Biología Molecular y Neurociencias (CONICET), Departamento de Fisiología y Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina

Abstract: Traditional approaches for risk assessment of ischemic heart disease (IHD) are based on the physiological consequences of an epicardial coronary stenosis. Of note, normal coronary arteries or nonobstructive coronary artery disease (CAD) is a common finding in women with signs and symptoms of ischemia. Therefore, assessment of risk based on a coronary stenosis approach may fail in women. Positron emission tomography (PET) quantifies absolute myocardial blood flow (MBF) which may help to elucidate other mechanisms involved such as endothelial dysfunction and alterations in the smooth muscle cell relaxation responsible for IHD in women. The objective of the present review is to describe the current state of the art of PET imaging in assessing IHD in women with nonobstructive CAD.

Keywords: Women; ischemic heart disease (IHD); positron emission tomography (PET); coronary flow reserve (CFR)

Introduction

From 2003 to 2013, rates of death attributable to cardiovascular diseases have declined in the United States, but the burden is still high. In fact, in 2013 cardiovascular diseases accounted for 1 of every 3 deaths, and coronary artery disease (CAD) alone for 1 of every 7 deaths (1,2). Moreover, CAD is the most common single cause of death in Europe, resulting in 19% of deaths in men and 20% of deaths in women (3).

It is important to mention that mortality in women is still significantly affected by delayed detection of ischemic heart disease (IHD) (4). This can be related to the fact that women are not alert about their cardiovascular risk and the clinicians often underestimate women’s symptoms of IHD, with the consequent failure or delay for implementing gender-specific diagnosis (5).

Traditional approaches for risk assessment of IHD are based on the physiological consequences of an epicardial coronary stenosis. Noteworthy, normal coronary arteries or nonobstructive CAD evaluated by cardiac computed tomography (CT) or invasive coronary angiography is a common finding in women with symptoms of ischemia (6-10). Therefore, assessment of risk based on a coronary stenosis approach may fail in women. However, the evaluation of coronary microcirculation may uncover other mechanisms, such as endothelial and vascular smooth muscle dysfunction responsible for the disease (10).

Current evidence shows that women presenting signs and symptoms of myocardial ischemia in the absence of obstructive CAD do not have a good prognosis (5). In fact, the Women’s Ischemia Syndrome Evaluation (WISE) (11)
has shown that after 10 years of follow up, cardiovascular death or myocardial infarction occurred in 6.7% of women with no evident CAD, and in 12.8% of those with nonobstructive CAD. Furthermore, it is quite common persistent chest pain or worsening of the symptoms over the years (12).

Despite that widespread imaging techniques for the functional evaluation of CAD are single photon emission computed tomography (SPECT) and stress echocardiography, positron emission tomography (PET) has unique features that may help to reveal IHD in women: (I) the ability of quantify myocardial blood flow (MBF) in absolute units and to calculate coronary flow reserve (CFR); (II) a routine attenuation correction; and (III) a uniform independent resolution (13). These capabilities of PET can be useful because IHD in women may result from the interactions of many variables, such as focal stenosis, diffuse epicardial coronary narrowing, impaired endothelial shear stress and microvascular dysfunction, which difficult the diagnosis of the disease (14).

The present review will focus on assessment of coronary microvascular dysfunction, diagnosis and prognosis of IHD in women in absence of obstructive CAD as assessed by PET.

Assessing of coronary microvascular function by PET

CFR is a noninvasive measure of coronary vasomotor function that integrates the hemodynamic effects of epicardial coronary stenosis, diffuse atherosclerosis and microvascular dysfunction on myocardial tissue perfusion (13) (see Figure 1). CFR can be measured noninvasively by PET, transthoracic Doppler echocardiography and cardiovascular MRI (15). Dynamic PET imaging affords robust and reproducible measurements of absolute MBF in ml/min/g at rest and during pharmacological stress which allows the calculation of CFR (defined as the ratio between MBF at stress and MBF at rest) (13,16). Thresholds of MBF at rest in healthy individuals may vary between 0.4 to 1.2 mL/g/min and hyperemic MBF between 1.8 to 2.3 mL/g/min (depending on the PET flow tracer). For N-13 Ammonia and Rb-82, CFR less than 2 is considered abnormal (17). Of note, since CFR is a ratio, factors affecting measurements of resting and hyperemic MBFs may influence its calculation (16). Automated analysis programs are commercially available to calculate absolute MBF. In hybrid PET/CT scanners, list-mode acquisitions allow evaluation of MBF, myocardial perfusion and left ventricular function with a single injection of a tracer (18). Routine signal attenuation correction is performed with this technique both at rest and during stress. This is an important issue, because the breast attenuation on myocardial perfusion images is a common methodological problem in women that can cause artifacts in the anterior wall of the left ventricle. In the case of hybrid PET/CT instrumentation, a low dose CT is used for attenuation correction purposes and also for calculating coronary artery calcium score (19). Other important advantages for PET imaging are: (I) the low radiation dose for the patient as compared to conventional myocardial perfusion SPECT imaging (either with N-13 Ammonia or Rubidium-82 as flow tracers) (20); and (II) the short time of the study completion (between 30 to 90 minutes total, depending of the PET-tracer).

It is important to remark that the assessment of the coronary microcirculatory function by PET requires of certain pharmacological interventions. Typically, the flow responses to the application of smooth muscle vasodilators such as dipyridamole, adenosine or selective adenosine receptor agonists like regadenoson and binodenoson (21,22) maximally reduce the vascular resistance to flow in the microcirculation, and induce maximum or near-maximum hyperemia. All these compounds are direct coronary vasodilators, activating the adenosine (A2) receptors in the coronary arterial wall. In patients without CAD, adenosine and dipyridamole infusion increase coronary blood flow three to five times above baseline levels (23,24). On the other hand, in patients with obstructive and significant epicardial CAD, the MBF response to these pharmacological agents is diminished with the consequent reduction in CFR (25). MBF responses to these agents provide information ‘predominantly’ on the vascular smooth muscle function, but also on the integrated function of the coronary circulation. In fact, 20–40% of the maximal vasodilator response caused by dipyridamole or adenosine is related to the release of nitric oxide from intact endothelium due to increased shear stress on endothelial cells caused by the hyperemic response (26). Clinically, these vasodilators are used to assess global and regional CFR in patients with and without epicardial CAD (15).

There is some variability of MBF values throughout the spectrum of coronary atherosclerosis. This notion has been recently reviewed by Gould and collaborators (13). According to these authors, a possible explanation of such variability may be attributed to many factors such as the wide prevalence of subclinical respect to clinical CAD, the
presence of risk factors (hypertension, diabetes, cigarette smoking, hyperlipidemia) and also technical issues as the variability inherent to the technique itself (which is around 14% for normal PET MBF) (27-29). Therefore, clinical interpretation of MBF and derived CFR requires understanding range values (normal limits), the limitations of the technique and the biological variables that can affect these measurements (13,16).

Endothelium-mediated coronary vasomotor function can be determined by the cold pressor test (CPT) (30,31). Several reports have been published using CPT as a sympathetic stimulus in healthy volunteers and patients with cardiovascular risk factors, yielding a good correlation of angiographically established flow-dependent dilation and MBF measured by PET (32). This test involves immersion of a patient’s hand or foot in icy water for 90 s while the injection of a PET flow tracer is performed. Sympathetic activation by CPT induces noradrenaline release. The direct effect of noradrenaline on smooth muscle cells is vasoconstriction, which is mediated by activation of α1 and 2-adrenoceptors (33). When endothelial function is normal, this vasoconstrictor effect is counteracted by endothelial α2-adrenoceptor-mediated stimulation of nitric oxide release with a net increase in coronary flow (34). In contrast, when endothelial cell function is abnormal, the vasoconstrictive response to noradrenaline predominates, and therefore an attenuated MBF response to CPT is observed (30). Typically, an increase of more than 50% of MBF respect to the resting flow is considered a preserved endothelial function. The accuracy and reproducibility of PET MBF measurements during CPT have been validated in several studies (32,35-37).

CT angiography can be performed in conjunction with myocardial perfusion PET imaging. This noninvasive approach allows integrating epicardial anatomy with the extent and characteristics of nonobstructive disease, which has been related to microvascular coronary flow (38). The prognostic impact of nonobstructive CAD has been demonstrated with cardiac CT, especially using atherosclerotic burden indexes like the segment involvement score (SIS) (39) or the CT-Leaman score (40). Both indexes were able to identify that a subset of patients that had “only” nonobstructive CAD but by having a high (SIS >5 or CT-Leaman score >5) coronary atherosclerotic burden were at an increased risk for coronary events, in the range of what is expected for the traditionally considered higher risk patients of the obstructive CAD subset.

In parallel, CT coronary angiography has evolved to evaluate the hemodynamic significance of coronary lesions by several approaches, including stress myocardial perfusion, fractional flow reserve (FFR)-CT, transluminal attenuation gradients, atherosclerotic plaque burden and characteristics, and more recently, CFR by means of dynamic CT perfusion acquisition techniques (41-43) (see Figure 1).

**Diagnostic accuracy and prognostic value of PET in women**

Current literature supports a high diagnostic accuracy for cardiac PET perfusion imaging. The reasons for this are multiple including routine attenuation correction, image quality, as well as the properties of PET tracers that follow MBF in a more linear fashion than SPECT tracers (44). A meta-analysis of the cardiac PET literature demonstrated high sensitivity (92%) and specificity (85%) for the detection of CAD (45). Two meta-analyses comparing Rubidium-82 and N-13 Ammonia PET data to SPECT confirmed the diagnostic accuracy. Both demonstrated a higher diagnostic accuracy for PET with a 3-5% increase in specificity and 4-5% increase in sensitivity (46,47) (see Table 1).
Myocardial perfusion imaging with PET has a high diagnostic accuracy for both women and men, which is higher than conventional SPECT (88% vs. 67%, \( P=0.009 \)) (48). In particular, in the PET Prognosis Multicenter Registry, Kay et al. (49) described in a total of 6,307 women and men that stress myocardial perfusion with Rb-82 provided significant and clinically meaningful risk stratification in both genders. There was a proportional relationship between CAD mortality and stress Rb-82 PET myocardial perfusion defect size and extent, as assessed by percentage of myocardium involved (see Figure 2). The unadjusted 5-year CAD mortality ranged from 0.9% to 12.9% for women (\( P<0.0001 \)) and from 1.5% to 17.4% for men (\( P<0.0001 \)) for 0% to \( \geq 15% \) abnormal myocardium at stress. Importantly, in this study the percentage of abnormal stress myocardium was independently predictive of CAD mortality in both men and women. The finding of sex equity in risk stratification with Rb-82 PET supports comparability with evidence from SPECT and other stress imaging modalities (49).

### Identification and prognostic value of microvascular dysfunction in women: role of quantification of MBF by PET

Identification and quantification of microvascular dysfunction are responsible for their symptoms and the disease (14). Moreover, symptomatic women with chest pain undergoing coronary angiography may exhibit normal or insignificant CAD in up to 50% of the cases (5). In this scenario, establishing the diagnosis based on the relative distribution of a flow tracer in the myocardium may underestimate their risk. Instead, absolute quantification of MBF can identify more accurately women at risk in absence of obstructive CAD (see Figure 3).

In fact, impaired CFR and abnormal coronary vascular responsiveness to CPT have been reported in women with risk factors for CAD and without stress-regional myocardial perfusion defects (50-53). These functional alterations at microcirculation level in women at risk for IHD are in agreement with observations using dynamic PET imaging in patients with traditional coronary risk factors (33,51,54,55). For example, Di Carli et al. (56) using PET imaging have compared MBF responses to CPT and during maximal hyperemia in three groups of asymptomatic women: healthy premenopausal women, premenopausal women with diabetes and healthy postmenopausal women. All women exhibited normal relative myocardial perfusion PET scans at rest and during stress. However, absolute measurements of MBF showed a diminished CFR and an impaired response of MBF to CPT in diabetic premenopausal women, similar to those observed in postmenopausal women. Thus, the presence of diabetes removes the protective vascular effects observed in premenopausal women which have prognostic implications that can be detected by dynamic PET imaging (57).

### Table 1 Diagnostic accuracy of cardiac PET vs. SPECT for detecting CAD

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mc Ardle et al. [2012]</th>
<th>Parker et al. [2012]</th>
<th>Bateman et al. [2006]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>3,099</td>
<td>11,862</td>
<td>224</td>
</tr>
<tr>
<td>Type of study</td>
<td>Meta-analysis</td>
<td>Meta-analysis</td>
<td>Single-center study</td>
</tr>
<tr>
<td>Isotope</td>
<td>PET Rb-82</td>
<td>Rb-82/(^{13})N Ammonia</td>
<td>Rb-82</td>
</tr>
<tr>
<td></td>
<td>SPECT Tc 99m-sestamibi</td>
<td>Tc 99m-sestamibi</td>
<td>Tc 99m-sestamibi</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>PET 90%</td>
<td>92%</td>
<td>86%</td>
</tr>
<tr>
<td></td>
<td>SPECT 85%</td>
<td>88%</td>
<td>81%</td>
</tr>
<tr>
<td>Specificity</td>
<td>PET 88%</td>
<td>81%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>SPECT 85%</td>
<td>75%</td>
<td>66%</td>
</tr>
</tbody>
</table>

PET, positron emission tomography; SPECT, single photon emission computed tomography; CAD, coronary artery disease.
Figure 2 Prognostic value of myocardial perfusion positron emission tomography: results from a multicenter observational registry [with permission from Kay et al. (49)].

![Graph showing cumulative CAD mortality rate for women and men.](image)

Stratified cox model $X^2=154, p<0.0001$

Comparative CAD mortality estimates from the PET Prognosis Registry in women and men. In women and men, the percentage of the myocardium that was abnormal was associated with a graded increase in CAD mortality. CAD = coronary artery disease; PET = positron emission tomography.

Figure 3 A seventy-nine-year-old woman with stable angina. She has history of hypertension and hypercholesterolemia. PET short-axis cuts at rest, during CPT and during DIP induced hyperemia shows a preserved relative myocardial perfusion, in absence of coronary atherosclerosis (as shown by calcium score of 0), left panel. She exhibits a normal coronary angiogram (mid panel). Polar maps of quantification of MBF by PET shows a borderline CFR and an abnormal flow increase to CPT, suggesting that the patient has endothelial dysfunction at the level of the microcirculation (right panel). PET, positron emission tomography; CPT, cold pressor test; DIP, dipyridamole; MBF, myocardial blood flow; CFR, coronary flow reserve.
The WISE study reported a subgroup of symptomatic women for chest pain with non-obstructive CAD that showed a microvascular dysfunction (defined as CFR <2.5 in response to adenosine, as evaluated by PET) distributed heterogeneously in the myocardium (58). The investigators found that resting absolute MBF was significantly higher in the left anterior descending coronary artery territory than in the left circumflex coronary artery and right coronary artery territories. Accordingly, a comparison of the CFR in the three coronary arteries demonstrated that the left circumflex coronary artery distribution had lower values than the other two vascular territories. This finding suggests that microvascular dysfunction manifested by impaired CFR may be a localized process, which is distributed heterogeneously in the myocardium in symptomatic women.

Abnormal MBF responses to CPT and an impaired CFR are associated with future cardiac events in both men and women even in absence of epicardial obstructive CAD (36,59-62). Importantly, noninvasive assessment of coronary microcirculation function by PET provides incremental risk stratification beyond measures of clinical risk, including estimations of left ventricular systolic function and the extent and severity of myocardial ischemia (by semiquantitative analysis), resulting in an incremental risk reclassification of patients with known or suspected CAD (59-62).

Naya et al. (63) have shown that a preserved CFR has a high negative predictive-value for excluding high-risk CAD on coronary angiography. On the other hand, although an abnormal CFR increases the likelihood of significant obstructive CAD, it cannot differentiate significant epicardial stenosis from nonobstructive disease, diffuse atherosclerosis or microvascular dysfunction.

Interestingly, it has been described the association between CFR, angiographic CAD and cardiovascular outcomes (64). The authors included 329 patients referred for coronary angiography after stress PET and followed by a median of 3.1 years. They found a modest correlation between CFR and CAD prognostic index and both parameters were independently associated with cardiac events. Patients with low CFR experienced rates of events similar to those of subjects with high angiographic scores, and those with low CFR who underwent coronary revascularization by CABG experienced event rates comparable to those with preserved CAD (independently of revascularization). Thus, based on this observational study global CFR confers risk independently of luminal angiographic severity. This is an attractive concept which has recently been explored in symptomatic women and men without CAD. Murthy et al. (65) investigated 405 men and 813 women referred for evaluation of suspected CAD and without myocardial perfusion defects at rest and during stress by PET. Major cardiac events (MACE) were assessed over a median follow-up of 1.3 years. Coronary microvascular dysfunction (CFR <2) was a powerful predictor of MACE, both in men and women despite normal stress perfusion imaging by PET.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Murthy et al. [2011]</th>
<th>Taqueti et al. [2016]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>1,218 (67% women)</td>
<td>329 (43% women)</td>
</tr>
<tr>
<td>End point</td>
<td>MACE (n=75)</td>
<td>MACE (n=74)</td>
</tr>
<tr>
<td>Follow up, years</td>
<td>1.3</td>
<td>3</td>
</tr>
<tr>
<td>PET tracer</td>
<td>$^{13}$N Ammonia/Rb-82</td>
<td>$^{13}$N Ammonia/Rb-82</td>
</tr>
<tr>
<td>Preserved CFR</td>
<td>&gt;2</td>
<td>&gt;2</td>
</tr>
<tr>
<td>Major findings</td>
<td>Coronary microvascular dysfunction (as defined as CFR &lt;2) was a powerful incremental predictor of MACE, both in men and women despite normal stress perfusion imaging by PET</td>
<td>As compared to men, women referred for invasive evaluation of CAD demonstrated less obstructive epicardial CAD, but greater adjusted risk of cardiovascular events. Only women with severely impaired coronary flow reserve (&lt;1.6) demonstrated increased risk relative to men</td>
</tr>
</tbody>
</table>

PET, positron emission tomography; CFR, coronary flow reserve; MACE, major adverse cardiac events; CAD, coronary artery disease.
quantification of MBF may allow reclassifying their risk (see Figure 4).

Conclusions and future directions

Taken all together, symptomatic women with nonobstructive CAD are at risk when coronary vascular dysfunction is present. Observational studies have demonstrated that PET imaging can identify coronary microvascular dysfunction and predict outcomes in women with IHD. Randomized and multicenter studies are needed to standardize the routine clinical application of quantification of PET-MBF and CFR in such patients. Of note, in the current multimodality imaging era we can evaluate the whole spectrum of the atherosclerosis process and predict risk. Further studies are warranted to explore the complementary role of cardiac imaging techniques to identify women at risk.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


35. Schindler TH, Czernin J, Schelbert HR, et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are...


Cite this article as: Campisi R, Marengo FD. Coronary microvascular dysfunction in women with nonobstructive ischemic heart disease as assessed by positron emission tomography. Cardiovasc Diagn Ther 2017;7(2):196-205. doi: 10.21037/cdt.2017.04.08